Pharsight Corporation and FDA Collaboration Continues: CRADA Delivers Phoenix NLME and Phoenix Connect to Market

Published: Jan 05, 2010

ST. LOUIS--(BUSINESS WIRE)--Pharsight, a market-leading provider of software and scientific services to improve productivity and decision-making in clinical drug development, today announced that it has released two new data analysis tools; Phoenix NLME and Phoenix Connect. The tools were developed via a collaborative effort between FDA and Pharsight under Pharsight’s previously-announced Cooperative Research and Development Agreement (CRADA) with FDA’s Center for Drug Evaluation and Research (CDER).

Back to news